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Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed for the
treatment of acute and chronic inflammation, pain and fever. However, long-term clini-
cal usage of NSAIDs is associated with significant side effects such as gastrointestinal le-
sions, bleeding, and nephrotoxicity. Therefore, discovery of new safer anti-inflammatory
drugs represents a challenging goal in a research area (1–4). In our ongoing medicinal
chemistry research program, we found that quinazolines and condensed quinazolines
exhibit potent central nervous system (CNS) activity, including analgesic, anti-inflam-
matory (5) and anticonvulsant behavior (6). Quinazolin-4(3H)-ones with 2,3-substitution
are reported to possess significant analgesic, anti-inflammatory (7, 8) and anticonvulsant
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A series of novel 3-cyclohexyl-2-substituted hydrazino-
-quinazolin-4(3H)-ones were synthesized by reacting the
amino group of 3-cyclohexyl-2-hydrazino quinazolin-
-4(3H)-one with a variety of aldehydes and ketones. The
starting material, 3-cyclohexyl-2-hydrazino quinazolin-
-4(3H)-one, was synthesized from cyclohexyl amine. Ti-
tle compounds were investigated for analgesic, anti-infla-
mmatory and ulcerogenic behavior. The compound 3-cy-
clohexyl-2-(1-methylbutylidene-hydrazino)-3H-quinazo-
lin-4-one (4c) emerged as the most active compound of
the series and is moderately more potent in its analgesic
and anti-inflammatory activities compared to the refer-
ence standard diclofenac sodium. Interestingly, test com-
pounds showed only mild ulcerogenic potential when
compared to acetylsalicylic acid.
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activitiy (9). We have earlier documented that some lead 2-phenyl-3-substituted quina-
zolines (10) (Fig. 1, I), 2-methyl-3-substituted quinazolines (11) (Fig. 1, II), 2-methylthio-
-3-substituted quinazaolines (12) (Fig. 1, III), and 2,3-disubstituted quinazolines (13) ex-
hibited good analgesic and anti-inflammatory properties. The present work is an exten-
sion of our ongoing efforts towards the development and identification of new mole-
cules for analgesic and anti-inflammatory activities with minimal gastrointestinal ulcer-
ation side effects. Against this background, in the present study we have synthesized a
series of 3-cyclohexyl-2-substituted amino-quinazolin-4(3H)-ones. The synthesized compo-
unds were tested for their analgesic, anti-inflammatory and ulcerogenic behavior.
EXPERIMENTAL
Melting points were taken in open capillaries on a Thomas Hoover melting point
apparatus (Thomas Hoover, USA) and are uncorrected. IR spectra were recorded in film
or in potassium bromide disks on a Perkin-Elmer 398 spectrometer (Perkin-Elmer, USA).
1H spectra were recorded on a DPX-300 MHz Bruker FT-NMR spectrometer (Bruker,
USA). Chemical shifts were reported as parts per million (d ppm) with tetramethylsilane
(TMS) as an internal standard. Mass spectra were obtained on a Jeol-SX-102 instrument
(Jeol, Japan) using fast atom bombardment (FAB positive). Elemental analysis was per-
formed on a Perkin-Elmer 2400 CHN analyzer (Perkin-Elmer) and values were within
acceptable limits of the calculated values (± 0.4%). Spectral data (IR, NMR and mass
spectra) and elemental analysis data are presented in Tables I and II. The progress of the
reaction was monitored on ready-made silica gel plates (Merck, Norway) using chloro-
form/methanol (9:1) as a solvent system. Iodine was used as a developing agent. All
chemicals and reagents used in the synthesis were obtained from Aldrich (USA), Lancas-
ter (USA) or Spectrochem (India) and were used without further purification.
Syntheses
3-Cyclohexyl-2-thioxo-2,3-dihydro-1H-quinazolin-4-one (1). – A solution of cyclohexyl
amine (0.02 mol) in dimethyl sulphoxide (10 mL) was stirred vigorously. To this, carbon
disulphide (1.6 mL) and aqueous sodium hydroxide 1.2 mL (2 mol L–1) were added drop-
wise during 30 min under stirring. Dimethyl sulfate (0.02 mol) was added gradually
keeping the reaction mixture stirred in a freezing mixture for 2 h. The reaction mixture
was then poured into ice water. The solid obtained was N-cyclohexyl-methyl dithiocar-
bamic acid, which was filtered, washed with water, dried and recrystallized from etha-
nol. Methyl anthranilate (0.01 mol) and the prepared N-cyclohexyl-methyl dithiocarbamic
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Fig. 1. Lead molecules of quinazolin-4-ones.
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a Molecular mass determination by mass spectral analysis (M+).
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acid (0.01 mol) were dissolved in ethanol (20 mL). To this, anhydrous potassium carbon-
ate (100 mg) was added and refluxed for 20 h. The reaction mixture was cooled in ice
and the solid separated was filtered and purified by dissolving in 10 % alcoholic sodium
hydroxide solution and re-precipitated by treatment with dilute hydrochloric acid. The
solid obtained was filtered, washed with water, dried and recrystallized from ethanol.
3-Cyclohexyl-2-methylsulfanyl-3H-quinazolin-4-one (2). – 3-Cyclohexyl-2-thioxo-2,3-di-
hydro-1H-quinazolin-4-one (1) (0.01 mol) was dissolved in 40 mL of 2 % alcoholic sodium
hydroxide solution. To this, dimethylsulfate (0.01 mol) was added dropwise under stir-
ring. The stirring was continued for 1 h, the reaction mixture was then poured into ice
water. The solid obtained was filtered, washed with water, dried and recrystallized from
the ethanol/chloroform (75:25) mixture.
3-Cyclohexyl-2-hydrazino-3H-quinazolin-4-one (3). – 3-Cyclohexyl-2-methylsulfanyl-
3H-quinazolin-4-one (2) (0.01 mol) was dissolved in ethanol (25 mL). To this, hydrazine
hydrate (99 %) (0.1 mol) and anhydrous potassium carbonate (100 mg) were added and
refluxed for 29 h. The reaction mixture was cooled and poured into ice water. The solid
so obtained was filtered, washed with water, dried and recrystallized from the chloro-
form/benzene (25:75) mixture.
General synthetic procedure for 3-cyclohexyl-2-substituted hydrazino-3H-quinazolin-4-
-ones (4a-o). – A mixture of 3-cyclohexyl-2-hydrazino-3H-quinazolin-4-one (3) (0.004 mol)
and appropriate ketone/aldehyde (0.004 mol) in glacial acetic acid was refluxed for 41 h.
The reaction mixture was poured into ice water. The solid obtained was filtered, washed
with water, dried under high vacuum and recrystallized from ethanol.
Pharmacology
The synthesized compounds were evaluated for analgesic, anti-inflammatory and
ulcerogenic activity. Test compounds and standard drugs were administered in the form
of a suspension (1 % carboxymethylcellulose as a vehicle) by oral route of administra-
tion for analgesic and anti-inflammatory studies, but for ulcerogenicity studies intrape-
ritoneally as suspension in 10 % (V/V) Tween 80. Each group consisted of six animals.
The animals were maintained in colony cages at 25 ± 2 °C, relative humidity of 45–55 %,
under a 12 h light and dark cycle; they were fed standard animal feed. All the animals
were acclimatized for a week before the experiment. The Institutional Animal Ethics
Committee approved the protocol adopted for experimentation on animals.
Analgesic activity. – Test for analgesic activity was performed by the tail-flick tech-
nique (14, 15) using Wistar albino mice (25–35 g) of either sex selected by random sam-
pling technique. Diclofenac sodium, at dose levels of 10 and 20 mg kg–1, was adminis-
tered orally as reference drug for comparison. The test compounds at two dose levels (10
and 20 mg kg–1) were administered orally. The reaction time was recorded at 30 min, 1, 2
and 3 h after the treatment, and the cut-off time was 10 s.
Anti-inflammatory activity. – Anti-inflammatory activity was evaluated by the carra-
geenean-induced paw oedema method (16). Sixteen groups of albino Wistar rats of ei-
ther sex weighing 150–200 g, 6 animals each, were orally dosed with the tested compo-
unds at two dose levels (10 and 20 mg kg–1). Diclofenac sodium, 10 and 20 mg kg–1, was
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administered as standard drug for comparison. Paw volumes were measured using the
mercury displacement technique with the help of a plethysmograph immediately after and
30 min, 1, 2 and 3 h after carrageenean injection.
Ulcerogenicity index. – Wistar Albino rats weighing 150–200 g, of either sex, were di-
vided into sixteen groups of six animals each (17). Animals were administered the test
compounds intraperitoneally at a dose of 20 mg kg–1 (17). The control group of animals
was administered only 10 % (V/V) Tween 80 suspension intraperitoneally. One group was
administered acetylsalicylic acid (Ranbaxy, India) intraperitoneally at a dose of 20 mg
kg–1 once daily for three days. On the fourth day, pylorus was ligated as per the repor-
ted method (18). Animals were fasted for 36 h before the pylorus ligation procedure. Four
hours after the ligation, animals were sacrificed. The stomach was removed and opened
along the greater curvature. Ulcer index was determined by the reported method (19).
Statistical analysis
Statistical analysis of the biological activity of synthesized compounds on animals
was evaluated using a one-way analysis of variance (ANOVA). In all cases, posthoc com-
parisons of the means of individual groups were performed using Tukey’s test. All valu-
es were expressed as mean ± SD. The GraphPad Prism 3.0 version was used for statisti-
cal analysis.
RESULTS AND DISCUSSION
The key intermediate 3-cyclohexyl-2-thioxo-2,3-dihydro-1H-quinazolin-4-one (1) was
prepared from cyclohexyl amine with carbon disulphide and sodium hydroxide in di-
methyl sulphoxide to give sodium dithiocarbamate, which was methylated with dime-
thyl sulfate to afford the dithiocarbamic acid methyl ester. The later refluxed with me-
thyl anthranilate in ethanol yielded the desired compound 1 via the thiourea intermedi-
ate in a good yield. IR spectra of compound 1 showed intense peaks at 3298 cm–1 for cy-
clic thiourea (NH), 1690 cm–1 for carbonyl (C=O) and 1218 cm–1 for thioxo (C=S) stretch-
ing. 1H NMR spectrum of 1 showed a multiplet at d 0.91–2.02 and 7.33–7.84 ppm for
cyclohexyl (10H) protons and aromatic (4H) protons, respectively, and a singlet at d 10.35
ppm, indicating the presence of NH. Further, the molecular ion recorded (m/z 260 [M+])
in the mass spectrum is also in agreement with the molecular mass of the compound.
3-Cyclohexyl-2-methysulfanyl-3H-quinazolin-4-one (2) was obtained by dissolving
1 in 2 % alcoholic sodium hydroxide solution and methylating with dimethyl sulfate un-
der stirring at room temperature. The IR spectrum of compound 2 showed disappear-
ance of NH and C=S stretching signals of cyclic thiourea. It showed a peak for carbonyl
(C=O) stretching at 1690 cm–1. The 1H NMR spectrum of compound 2 showed singlets
due to SCH3, a multiplet at d 1.10–2.21 and 7.22–7.73 ppm for cyclohexyl (10H) protons
and aromatic (4H) protons, respectively. Molecular ion recorded in the mass spectrum
(m/z 274 [M+]) further confirmed the assigned structure.
Nucleophilic displacement of the methylthio group of 2 with hydrazine hydrate was
carried out using ethanol as solvent to afford 3-cyclohexyl-2-hydrazino-3H-quinazolin-
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-4-one (3). The long duration of reaction (29 h) required might be due to the presence of
the bulky cyclohexyl ring at position 3, which might have reduced the reactivity of qui-
nazoline ring system at the C-2 position. The formation of 3 was confirmed by the 1H
NMR spectrum singlets at d 4.32 and 9.73 ppm due to NH2 and NH, respectively, a mul-
tiplet at d 0.80–1.91 and 7.24–7.65 ppm for cyclohexyl (10H) protons and aromatic (4H)
protons, respectively. The NH and NH2 signals at 3330–3261 cm–1 appeared in the IR
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spectrum. It also showed a peak for carbonyl (C=O) at 1680 cm–1. Further, the molecular
ion recorded in the mass spectrum (m/z 258 [M+]) is also in agreement with the molecu-
lar mass of the compound.
The title compounds, 3-cyclohexyl-2-substituted hydrazino-3H-quinazolin-4-ones
(4a-o), were obtained by condensation of the amino group of 3-cyclohexyl-2-hydrazino-
-3H-quinazolin-4-one (3) with a variety of aldehydes and ketones. Formation of the title
product is indicated by the disappearance of peak due to NH2 of the starting material in
IR and 1H NMR spectra of all compounds 4a-o. The IR and 1H NMR spectra of these
compounds showed the presence of peaks due to (N=CR1R2), carbonyl (C=O), NH and
aryl groups. Mass spectra of the title compounds showed molecular ion peaks correspon-
ding to their molecular formula. In mass spectra of compounds 4a-o, a common peak at
m/z 144 corresponding to quinazolin-4-one moiety appeared. The M++2 peaks were ob-
served in the spectra of compounds 4h and 4i, confirming the presence of a chlorine atom
in the compounds. The relative intensities of these M++2 peaks in comparison with M+
peaks were in a ratio 1:3. Elemental analysis satisfactorily confirmed elemental composi-
tion and purity of the synthesized compounds.
The results of analgesic testing indicated that the test compounds exhibited moder-
ate analgesic activity after 30 min of reaction time and an increase in activity after 1 h,
reaching the peak level after 2 h. Decline in activity was observed after 3 h (Table III).
Compound 4a with 1-methylpropylidene substituent showed good activity; with increa-
sed lipophilicity of 1-ethylpropylidene group compound 4b showed an increase in activ-
ity. After replacement of 1-ethylpropylidene group with its isomer 2-pentylidene group
compound 4c retained its activity. Replacement of an alkyl chain at the 2-position with a
cycloalkyl group and an aralkyl group (compounds 4d and 4e, respectively) led to mode-
rate decrease in activity. Placement of an aryl group at the N-3 position (compounds 4f,
4g and 4m-o) also resulted in decreased activity. Placement of an electron withdrawing
group at the N-3 aryl ring (compounds 4h-l) led to further decrease of activity.
The anti-inflammatory activity data (Table IV) indicate that all the test compounds
moderately protected rats from carrageenean-induced inflammation after 30 min of re-
action time, with increased activity after 1 h that reached the peak level after 2 h. Decline
in activity was observed after 3 h. Compound 3-cyclohexyl-2-(1-methyl butylidene-hy-
drazino)-3H-quinazolin-4-one (4c) emerged as the most active anti-inflammatory agent
and it is more potent compared to the reference standard diclofenac sodium.
The ulcer index of the test compounds (Table V) reveals that the compounds with
open-chain aliphatic substituents (compounds 4a-c) showed a negligible ulcer index, whe-
reas aryl substituents (compounds 4e-g and 4m-o) exhibited little increase in the ulcer
index and the aryl substituents containing electron withdrawing groups (compounds 4h-l)
exhibited a higher ulcer index then other test compounds. When compared to the refer-
ence standard acetylsalicylic acid (ulcer index 1.73 ± 0.41) and diclofenac (ulcer index
1.65 ± 0.59), the test compounds exhibited about 35 to 50 % of the ulcer index of refer-
ence standards. Compound 3-cyclohexyl-2-(1-methylpropylidene-hydrazino)-3H-quina-
zolin-4-one (4a) exhibited the lowest ulcer index (0.45 ± 1.51) among the test compounds
wherease the compound 3-cyclohexyl-2-(N’-(2-nitro-benzylidene-hydrazino)-3H-quina-
zolin-4-one (4j) showed the highest ulcer index (0.79 ± 1.26) among the test compounds.
In our earlier studies, we observed that the presence of alkyl groups exhibited more
analgesic and anti-inflammatory activities then aryl groups at the N-3 position of qui-
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a Mean ± SD from six experiments done in duplicate.
b Control animals were administered orally 1 % CMC.
Significant difference relative to diclofenac at the same time point and the same dosage: c p < 0.0001,
d p < 0.001, e p < 0.01.
85
V. Alagarsamy et al.: Synthesis and pharmacological evaluation of 3-cyclohexyl-2-substituted hydrazino-3H-quinazolin-4-ones as
analgesic and anti-inflammatory agents, Acta Pharm. 59 (2009) 75–88.





















































































































































































a Mean ± SD from six experiments done in duplicate.
b Control animals were administered orally 1 % CMC.
Significant difference relative to diclofenac at the same time point and the same dosage: c p < 0.0001,
d p < 0.001, e p < 0.01.
nazolin-3-yl-4(3H)-one (10-13). Hence, we also made a substitution at the C-2 position in
such a way as to increase lipophilicity of the molecule. Placement of such a group en-
hanced the analgesic and anti-inflammatory activities. In the present study, the most ac-
tive compound 4c exhibited 77 and 85 % analgesic activity at 10 and 20 mg kg–1, dose le-
vels respectively, after 2 h. In contrast, diclofenac sodium showed 45 and 62 % analgesic
activity at 10 and 20 mg kg–1 dose levels, respectively, after 2 h. The most active com-
pound 4c showed 63 and 74 % anti-inflammatory activity at doses of 10 and 20 mg kg–1,
respectively, after 2 h, whereas diclofenac sodium revealed 39 and 60 % anti-inflamma-
tory activity at doses of 10 and 20 mg kg–1, respectively, after the same time. Interestingly,
compound 4c showed 35 % of ulcer index of the reference NSAID’s acetylsalicylic acid
and diclofenac.
CONCLUSIONS
In the present study, synthesis of a new series of 3-cyclohexyl-2-substituted hydra-
zino-3H-quinazolin-4-ones (4a-o) has been described. Among the series, 3-cyclohexyl-2-
-(1-methylbutylidene-hydrazino)-3H-quinazolin-4-one (4c) emerged as the most active
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Table V. Ulcerogenicity
Compd. Ulcer indexa
4a 0.45 ± 1.51
4b 0.50 ± 1.82
4c 0.50 ± 1.75
4d 0.48 ± 1.64
4e 0.61 ± 1.23
4f 0.66 ± 1.42
4g 0.64 ± 1.82
4h 0.71 ± 1.21
4i 0.73 ± 1.54
4j 0.79 ± 1.26
4k 0.74 ± 1.71
4l 0.77 ± 1.21
4m 0.58 ± 1.23
4n 0.60 ± 1.84
4o 0.59 ± 1.65
Controlb 0.15 ± 0.33c
Diclofenac 1.65 ± 0.59
Acetylsalicylic acid 1.73 ± 0.41
a Mean ± SD from six experiments done in duplicate.
b Control animals were administered 10 % (V/V) Tween 80 (i.p.).
Significant difference relative to diclofenac: c p < 0.0001.
compound and it is moderately more potent in its analgesic and anti-inflammatory ac-
tivities compared to the reference standard diclofenac sodium. Although this series could
be developed as a novel class of analgesic and anti-inflammatory agents, further struc-
tural modifications are planned to increase the analgesic and anti-inflammatory activities
with reduced ulcerogenicity.
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S A @ E T A K
Sinteza i farmakolo{ka evaluacija 3-cikloheksil-2-supstituiranih
hidrazino-3H-kinazolin-4-ona kao analgetika i antiinflamatorika
VEERACHAMY ALAGARSAMY, DURAIRAJ SHANKAR, VISWAS RAJA SOLOMON,
RAJENDRA VASANT SHEOREY i PERIYASAMY PARTHIBAN
Reakcijom amino skupine 3-cikloheksil-2-hidrazino kinazolin-4(3H)-ona s razli~itim
aldehidima i ketonima sintetizirani su novi 3-cikloheksil-2-supstituirani hidrazino-kina-
zolin-4(3H)-oni. Po~etni spoj 3-cikoheksil-2-hidrazino kinazolin-4(3H)-on pripravljen je
iz cikloheksilamina. Sintetizirani spojevi testirani su na analgetsko i protuupalno djelo-
vanje te ulcerogena svojstva. Spoj 3-cikloheksil-2-(1-metilbutiliden-hidrazino)-3H-kina-
zolin-4-on (4c) imao je najja~e analgetsko i protuupalno djelovanje, ne{to ja~e nego re-
ferentni spoj diklofenak natrij. Osim toga, testirani spojevi imaju samo blago ulcerogeno
djelovanje u usporedbi s acetilsalicilnom kiselinom.
Klju~ne rije~i: kinazolin-4(3H)-on, analgetsko djelovanje, protuupalno djelovanje, ulcerogenost
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